TFS HealthScience has been accredited in Medidata Rave RTSM to conduct randomization and drug trial supply management services
STOCKHOLM, July 26, 2021 /PRNewswire/ -- This accreditation enables TFS to address complex requirements characteristic of the current clinical research environment. Flexible approach and quick implementation of change helps us reach our clinical trial goals. As Medidata partner we are able to provide scalable solutions and create a complete value-driven experience for our biopharma customers.
"The accreditation in Medidata Balance® grows our portfolio of Medidata products and extends the successful partnership between TFS HealthScience and Medidata. Investing in cutting edge technology allows TFS to better serve our customers and demonstrates our commitment to patients", says Bassem Saleh, TFS CEO
TFS has aimed at the the accreditation in Balance to bring a number of benefits to our project management:
Patient randomization from within Rave
Unified EDC and RTSM solution and centralized operations
Reduced complexity and risk associated with the manual process
Configurable and reliable system giving potential to accelerate the study start-up
Simplified and tailored reporting
As Medidata partner since 2018. TFS HealthScience has previously been certified on Medidata Rave
For more information, please reach out to Sylwia Domagalska, Senior Director Marketing and Communications Email: [email protected] Phone: +48 787 913 074
Clarivate Plc , a leading global provider of transformative intelligence, today announced the launch of Epidemiology Intelligencetm. The new solution combines rich insights from epidemiology, incidence and prevalence database solutions. It includes...
Sciwind Biosciences Co., Ltd., a clinical stage biopharmaceutical company focused on developing treatments for metabolic disease, and HK inno.N Corporation, a South Korean commercial stage pharmaceutical company (KOSDAQ: 195940), today announced a...
Photocure ASA (OSE: PHO), the Bladder Cancer Company, announces its participation in the congress, and two abstract presentations at the AUA 2024: the American Urological Association Annual Congress 2024 was held May 3-6, 2024, in San Antonio, TX,...
The World Federation of Neurology (WFN) is pleased to announce Brain Health and Prevention as the theme for the 2024 World Brain Day (WBD 2024), taking place on Monday, July 22. The goal is to raise critical awareness to prevent brain disease in all...
Regulatory News:
Sensorion (FR0012596468 ? ALSEN) a pioneering clinical-stage biotechnology company which specializes in the development of novel therapies to restore, treat and prevent within the field of hearing loss disorders, today announces...
Modalis Therapeutics Corporation (Tokyo Stock Exchange: 4883), a pioneering company developing innovative drugs for the treatment of rare genetic diseases, utilizing its proprietary CRISPR-based epigenome editing technology CRISPR-GNDM®, posted the...